MARKET

PRPO

PRPO

PRECIPIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.300
+0.040
+3.17%
After Hours: 1.340 -0.02 -1.54% 16:46 01/24 EST
OPEN
1.200
PREV CLOSE
1.260
HIGH
1.340
LOW
1.160
VOLUME
136.58K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
1.160
MARKET CAP
29.52M
P/E (TTM)
-3.1500
1D
5D
1M
3M
1Y
5Y
Precipio Shares Up 7%; Traders Recently Circulate Name As Play On COVID Antigen Tests Available On Amazon; BZ NOTE: Test By Co. Manufacturing Partner Nirmidas Only Available Via Amazon Business Accounts
https://www.amazon.com/dp/B08XG2XVSF?ref=myi_title_dp
Benzinga · 12/23/2021 19:18
CODX, SM and PERI among pre market gainers
Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals
Seekingalpha · 11/29/2021 13:34
BRIEF-New York State Approves Precipio’S Hemescreen For POL Clinical Use
reuters.com · 11/18/2021 16:21
Seth Klarman's Top 3rd-Quarter Trades
GuruFocus News · 11/15/2021 21:06
Precipio Announces Q3-2021 and year-end Shareholder Update Call
Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2021 update call on Monday, November 15th...
GlobeNewswire · 11/01/2021 21:00
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Zacks.com · 10/07/2021 15:49
Seth Klarman's Translate Bio Stake Dissolved Upon Acquisition
GuruFocus News · 09/17/2021 17:19
Seth Klarman Dissolves Translate Bio Stake Upon Acquisition
GuruFocus News · 09/17/2021 17:19
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRPO. Analyze the recent business situations of PRECIPIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRPO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
High7.00
Average7.00
Low7.00
Current 1.300
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 31
Institutional Holdings: 2.66M
% Owned: 11.72%
Shares Outstanding: 22.71M
TypeInstitutionsShares
Increased
8
234.97K
New
3
45.53K
Decreased
7
202.51K
Sold Out
8
231.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.50%
Healthcare Equipment & Supplies
-0.18%
Key Executives
Non-Executive Chairman/Independent Director
Richard Sandberg
Chief Executive Officer/Director
Ilan Danieli
Chief Financial Officer
Carl Iberger
Chief Operating Officer
Ahmed Sabet
Vice President - Research & Development
Ayma Mohamed
Independent Director
Ronald Andrews
Independent Director
David Cohen
Independent Director
Jeffrey Cossman
Independent Director
Douglas Fisher
Independent Director
Kathleen Laporte
No Data
About PRPO
Precipio, Inc. is a cancer diagnostics and reagent technology company providing diagnostic products and services to the oncology market. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. The Company operate a cancer diagnostic laboratory located in New Haven.

Webull offers kinds of Precipio Inc stock information, including NASDAQ:PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.